MOTS-c: A Peptide Encoded Inside the Mitochondria

The short version

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is unusual in a fundamental way: it is encoded not in the chromosomes in the cell nucleus but inside a tiny piece of DNA that lives in mitochondria — the organelles that produce cellular energy. That origin means it is a mitochondrial-derived peptide, or MDP, a category that barely existed in the scientific literature before 2015.

The peptide is 16 amino acids long (MRWQEMGYIFYPRKLR). Its best-characterised action is to activate AMPK, a master metabolic switch, by interfering with the folate cycle inside cells — which improves glucose handling primarily in skeletal muscle ^[10]. In animal studies it increases physical performance in young, middle-aged and aged mice ^[11], and a 2024 study identified casein kinase 2 (CK2) as a direct molecular target ^[8].

The honest limit: almost all of this is in animals. The only published human data are biomarker associations in a haemodialysis patient cohort, not an intervention trial ^[9]. MOTS-c is not approved anywhere, it is treated as a prohibited substance in elite sport, and this page lists no human dose.

What it is

MOTS-c is a 16-amino-acid peptide, sequence MRWQEMGYIFYPRKLR, encoded by a short open reading frame within the mitochondrial 12S ribosomal RNA gene (MT-RNR1). It is highly conserved across mammalian species — an indicator that the sequence performs a functionally important role preserved through evolution.

It belongs to a small and recently characterised family of mitochondrial-derived peptides (MDPs), which also includes humanin and SHLP1-6. What makes MDPs notable is that they are secreted from the mitochondrion and act as signalling molecules affecting the rest of the cell — and in MOTS-c's case, the rest of the body. The fact that they are mitochondrially encoded makes them candidates for explaining some of the health associations tied to mitochondrial genetics, including ancestry-dependent variations in metabolic traits ^[10].

How it works

MOTS-c's best-characterised mechanism involves the folate cycle and purine biosynthesis. By inhibiting the enzyme MTHFD1L in the folate cycle, MOTS-c reduces de novo purine synthesis. This causes a build-up of an intermediate called AICAR, which in turn activates AMP-activated protein kinase (AMPK). AMPK is a central metabolic regulator: when it is activated, cells increase glucose uptake, fatty-acid oxidation, and mitochondrial biogenesis. The net effect, demonstrated primarily in skeletal muscle, is improved glucose handling and insulin sensitivity ^[10].

Under metabolic stress a second, distinct action is observed: MOTS-c translocates from the mitochondrion to the nucleus, where it regulates nuclear gene expression in an AMPK-dependent manner, including genes in the antioxidant-response-element (ARE) pathway through interaction with NRF2 — the first demonstration of retrograde signalling by a mitochondrially encoded peptide ^[12].

A 2024 study added precision to this picture: MOTS-c was shown to directly bind and activate casein kinase 2 (CK2). Tissue-specific CK2 modulation — activation in muscle, suppression in fat — underlies MOTS-c's effects on muscle glucose uptake and its prevention of skeletal-muscle atrophy ^[8].

What the research shows

CK2 as direct target. In cell-free assays, MOTS-c directly bound and activated CK2; in mice (young, aged, high-fat-diet and immobilised), this resulted in prevention of skeletal-muscle atrophy and enhanced muscle glucose uptake through tissue-specific CK2 modulation. This is the most molecularly precise finding for MOTS-c to date ^[8].

Physical performance in mice. Exercise induces endogenous MOTS-c expression in skeletal muscle and circulation. Exogenous MOTS-c significantly enhanced treadmill running capacity, grip strength and gait in young (2 months), middle-aged (12 months) and aged (22-23.5 months) mice — with the most striking effects in the oldest animals, where the improvement was highly significant (P=0.000002). This positions MOTS-c as an exercise-mimetic and regulator of age-dependent physical decline ^[11].

Nuclear translocation. Under metabolic stress, MOTS-c translocates to the nucleus and regulates ARE/antioxidant and metabolic gene expression through AMPK and NRF2, establishing a mitochondria-to-nucleus communication loop ^[12].

Mechanistic synthesis. A 2023 comprehensive review consolidated MOTS-c's encoding within MT-RNR1, its AMPK/folate-cycle mechanism, nuclear translocation, exercise-inducibility, and roles in metabolic, stress-adaptive and aging pathways — the modern framework for understanding the peptide ^[10].

Human biomarker association. In a prospective multicenter cohort of 94 chronic haemodialysis patients with a median 26.5-month follow-up, circulating MOTS-c was independently associated with a composite of all-cause mortality and non-fatal cardiovascular events (Cox HR 1.004, p=0.05), and adding MOTS-c improved risk-model discrimination (ROC AUC 0.727 to 0.743) ^[9]. This is observational data, not an intervention trial — the strongest available human signal but not efficacy evidence.

Reported effects, cautions and safety

MOTS-c occupies the most preliminary position in human evidence on this desk. Several specific cautions apply:

• No human efficacy trials. Every claim about exogenous MOTS-c improving metabolism, performance or aging derives from cell culture or animal studies (predominantly mice and rats). Human data are observational biomarker associations, not interventional outcomes ^[9].
• No validated human pharmacokinetics. There is no published measured human half-life, bioavailability or dose-response for exogenous MOTS-c. Rodent doses studied (0.5–15 mg/kg/day) cannot be extrapolated to humans ^[10].
• Research-chemical status. MOTS-c is not approved by any regulator and is sold only for laboratory research; product purity, identity and sterility vary by supplier and are not regulated as pharmaceuticals.
• Anti-doping prohibition. Anti-doping bodies (USADA/WADA) classify MOTS-c among peptide and metabolic-modulator agents prohibited at all times; athlete use can result in sanctions.
• Ancestry and genotype interactions. A pro-diabetogenic MOTS-c mtDNA variant (m.1382A>C) and ancestry-dependent differences in exercise responses suggest that effects are not uniform across populations ^[10].
• Marketplace claims outpace evidence. Consumer interest in fat loss, longevity and performance substantially exceeds the strength of the current clinical evidence, and this desk exists specifically to contextualise that gap.

No community-anecdote reports are compiled in this desk's source material for MOTS-c, so none are presented; the points above are drawn from the cited literature.

Where it fits in GH axis research

MOTS-c is the most mechanistically novel compound on this desk. Where tesamorelin operates at the level of pituitary receptor signalling and CJC-1295 is an engineered GHRH analogue extending that signal, MOTS-c works at the cellular metabolic machinery — inside mitochondria and at the AMPK node that coordinates energy use across tissues. Its connection to the GH/IGF-1 theme is metabolic overlap: AMPK-driven improvements in glucose handling and insulin sensitivity sit in the same functional space as the downstream effects of GH-axis activation, even though the molecular entry point is entirely different. The animal exercise and anti-atrophy data are compelling as a research direction; what is missing is any controlled human interventional work. See how it compares on the comparison page.